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Abstract
Germline mis-sense mutations affecting a single BRCA2 allele predispose humans to cancer.
Here, we identify a protein-targeting mechanism disrupted by the cancer-associated mutation,
BRCA2D2723H that controls the nuclear localization of BRCA2 and its cargo, the recombination
enzyme RAD51. A nuclear export signal (NES) in BRCA2 is masked by its interaction with a
partner protein, DSS1, such that point mutations impairing BRCA2-DSS1 binding render BRCA2
cytoplasmic. In turn, cytoplasmic mis-localization of mutant BRCA2 inhibits the nuclear retention
of RAD51, by exposing a similar NES in RAD51 usually obscured by the BRCA2-RAD51
interaction. Thus, a series of NES-masking interactions localizes BRCA2 and RAD51 in the
nucleus. Interestingly, BRCA2D2723H decreases RAD51 nuclear retention even when wildtype
BRCA2 is present. Our findings suggest a mechanism for regulation of the nucleo-cytoplasmic
distribution of BRCA2 and RAD51, and for its impairment by a heterozygous disease-associated
mutation.
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Introduction
Inherited germline mutations in a single copy of the BRCA2 tumor suppressor predispose to
breast, ovarian, pancreatic and other cancers (The Breast Cancer Linkage Consortium)1.
Somatic loss of the second allele occurs frequently in the tumors that develop in mutation
carriers2,3, as in the case of other tumor suppressors4, but is not always essential for
tumorigenesis5. Much evidence suggests that BRCA2 exerts its tumor suppressive function
in the cell nucleus through its role in the repair of DNA breaks by homologous
recombination6,7. BRCA2 controls the accumulation of the RAD51 recombinase enzyme at
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sites of DNA breakage in the nucleus8, nucleates RAD51 filament formation at single-strand
(ss)-double-strand (ds) DNA junctions9, and promotes RAD51 binding on ssDNA whilst
inhibiting dsDNA binding10-15. However, defective homologous recombination occurs
typically in cells lacking both BRCA2 alleles7, and so it remains unclear how heterozygous
cancer-associated mutations may compromise BRCA2’s function.
To address this issue, we have investigated the cellular effects of a common cancer-
associated BRCA2 mis-sense mutation (BRCA2 D2723H) in which Asp2723 is replaced by
His16. Unexpectedly, our studies reveal an unreported mechanism wherein the localization
of BRCA2 and RAD51 to the cell nucleus is governed by the masking of nuclear exclusion
signals (NESs) via protein-protein interactions. The BRCA2 D2723H mutant impairs this
mechanism, triggering decreased nuclear accumulation of RAD51, even when wildtype
BRCA2 is present, contributing to its deleterious effects in the heterozygous state. Thus, our
results link the nucleo-cytoplasmic translocation of the BRCA2 tumor suppressor to the
cellular mechanisms of disease following its germline inactivation.
Results
DSS1 binding to BRCA2 is critical for nuclear localization
Cancer-associated mis-sense mutations in human BRCA2 frequently occur in the region
spanning residues ~2500 to 285017, which mediates the interaction (Supplementary Fig 1a)
of BRCA2 with the small (70 amino acids (aa)), acidic protein DSS118,19. One of these
mutations, BRCA2 D2723H, which alters a single Asp residue at position 2723 in the 3418
aa BRCA2 protein to His, has been reported >30 times in the Breast Cancer Information
Core database (http://research.nhgri.nih.gov/bic/). Evidence from linkage analysis of human
kindreds16 and from functional studies on murine embryonic stem cells suggests that the
inheritance of BRCA2 D2723H is functionally deleterious20. Because the BRCA2 D2723H
mutation affects a key conserved residue (Supplementary Fig 1a) that directly contacts
DSS117, we first determined whether it affects the BRCA2-DSS1 interaction. We generated
a fragment of BRCA2 spanning the entire DSS1-binding domain (DBD) across residues
2461-2975, fused to a yellow fluorescent protein (SYFP), plus a nuclear localization signal
(NLS), and co-expressed it in human 293T cells with an mCherry-tagged form of full length
DSS1. The SYFP-DBD fragment is >70KDa and therefore requires a heterologous NLS to
allow nuclear localization. While the wildtype (WT) form of NLS-SYFP-DBD co-
immunoprecipitatedwith mCherry-DSS1 (Figure 1a), the D2723H mutant did not, despite
higher expression levels. Similarly, a mutant form of the DBD (W2725A), in which an
evolutionarily conserved Trp residue at position 2725 implicated in DSS1 binding21 is
altered to Ala, immunoprecipitated poorly with mCherry-DSS1.
Measurement of fluorescence resonance energy transfer (FRET) (Supplementary Fig 1b), a
near-field coupling effect, reports on specific intermolecular interactions when the
interacting fluorophores are approximately <5nm apart22. SYFP and mCherry are an
optimized FRET pair, with a Forster Radius of >5nm, and thus exhibit an enhanced FRET
efficiency compared to traditional blue-shifted fluorophore pairs23. We used Fluorescence
Lifetime Imaging Microscopy (FLIM) to measure FRET on the donor SYFP molecule,
which has a mono-exponential decay of fluorescence lifetime23 (Supplementary Fig 1c). Co-
transfection of mCherry-DSS1 with NLS-SYFP-DBD caused a significant decrease in SYFP
lifetime from 3200 to 2900 picoseconds on average, evidenced by time-correlated single
photon counting, suggestive of FRET through the direct interaction of these molecules
(Figure 1b and Supplementary Fig 1d). In contrast, the lifetime of NLS-SYFP-tagged
D2723H or W2725A mutants remained close to 3100 picoseconds, confirming that the
mutations directly inhibit the BRCA2 DBD-DSS1 interaction (Figure 1b). Human BRCA2
normally localizes to the cell nucleus via tandem nuclear localization signals (NLSs) at its
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extreme C-terminus24. In contrast, full-length BRCA2 harboring the D2723H mutation mis-
localized predominantly to the cytoplasm in transfected cells (Figure 1c) as previously
shown25. Interestingly, BRCA2 W2725A was similarly mis-localized (Figure 1c),
suggesting a correlation between the loss of DSS1 binding and cytoplasmic mis-localization.
DSS1 masks a Nuclear Exclusion Sequence in BRCA2
Neither the D2723H nor the W2725A mutations is predicted to alter the canonical NLSs
positioned in exon 27 of BRCA224. This prompted us to survey BRCA2 for NESs using the
NetNES algorithm, which employs neural networks to predict consensus motifs fitting the
pattern ϕ-x(1-3)- ϕ-x(1-3)- ϕ -x-ϕ, where ϕ is a hydrophobic amino acid (M,F,I,V or L), and
x is any amino acid 26. We detected 4 such potential NES motifs in the DSS1-binding region
of BRCA2 (Supplementary Fig 2a). One motif (aa 2682-2698, encoded in human BRCA2
exon 18) shows strong evolutionary conservation, particularly of the critical hydrophobic
residues (Figure 2a). This motif, when fused to SYFP was enough to induce nuclear
exclusion, in contrast to a control BRCA2-derived peptide of similar size (Figure 2b),
substantiating its function.
The cytoplasmic mis-localization of BRCA2 mutants carrying alterations that affect DSS1
binding, but not intrinsic NLS or NES motifs, raises the possibility that the BRCA2-DSS1
interaction ‘masks’ an NES of BRCA2. Consistent with this idea, the structure of a BRCA2-
DSS1 complex19 suggested that the residues critical for binding to exportins in the potential
NES spanning human BRCA2 aa 2682-2698, are obscured by DSS1 (Figure 2c). Moreover,
over-expression of DSS1 in cells expressing wildtype forms of either NLS-SYFP-DBD, or
full-length BRCA2, enhanced nuclear localization, whereas the D2723H or W2725A
mutants were not similarly affected (Supplementary Figs 2b-d). Together, these findings
speak to a model wherein the binding of DSS1 to BRCA2 is essential for its nuclear
retention, via the masking of an NES within the DBD.
BRCA2 masks a Nuclear Exclusion Sequence in RAD51
The RAD51 recombinase, a 37 kDa protein central to DNA repair by homologous
recombination27, binds directly to the BRC repeats of BRCA215,28, an interaction that is
essential for the efficient completion of recombination reactions10-14. Eight BRC repeats are
present in human BRCA2, and the structural basis of their interaction with RAD51 has been
characterized by crystallography as well as by structure-function analyses in mammalian
cells28,29. Interestingly, a NetNES analysis of human RAD51 identified a putative NES
spanning aa 245-260 (Figure 3a), with strong conservation across species (Figure 3b). This
NES lies within a recently identified binding site for the BRC repeats of BRCA229, and an
examination of the crystal structure reveals that key exportin-binding residues within this
RAD51 NES are likely to be masked when bound to BRCA2 (Figure 3c). The RAD51 NES
was sufficient to exclude YFP from the nucleus when fused to the fluorophore (Figure 3d).
Mutation of the S208-A209 residues in RAD51 abolished its binding to the BRC repeats in
BRCA2, while retaining its self-interaction30. This mutant localized to the cytoplasm when
expressed in DT40 cells lacking endogenous Rad51 (Figure 3e). These observations not only
confirm that the nuclear retention of RAD51 requires binding to BRCA2, but also
corroborate that a RAD51 NES is masked by interaction with the BRC repeats of BRCA2.
In vitro interaction of CRM1 with NESs in BRCA2 and RAD51
We have demonstrated here that putative NESs identified in the DSS1-binding domain of
BRCA2and in the BRCA2-binding region of RAD51share the expected consensus
characteristics, and can direct the nuclear exclusion of SYFP when fused to this
heterologous protein. However, Leu residues in NES-like motifs frequently contribute to the
buried hydrophobic cores of protein folds, and may therefore be inaccessible for interaction
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with the nuclear exportin CRM1 in their native context31,32.To address this issue, we tested
the ability of GST-tagged forms of the NES-containing domains of BRCA2 or RAD51 to
bind in vitro to recombinant CRM1 in the presence of an active GTP-bound Q69L form of
the essential co-factor Ran, under the experimental conditions described previously33. We
found (Figure 4a) that a GST-tagged recombinant protein encoding the DBD region of
BRCA2 bound to recombinant CRM1 in the presence of Ran-GTP (lane 3), whereas GST
alone did not (lane 1). Moreover, the addition of DSS1 inhibited this interaction (Figure 4a,
lane 4) in a dose-dependent manner (Figure 4b). These results prompted us to test the effect
of the D2723H mutation, which is expected to prevent DSS1 binding. Indeed, the D2723H
mutant form of the BRCA2 DBD interacted constitutively with CRM1, whether or not DSS1
was present (Figure 4a, lanes 5 and 6). Thus, our findings provide biochemical evidence that
the DBD region of BRCA2 contains authentic NES motifs capable of binding CRM1, that
this interaction is lost when the NESs are ‘masked’ by the binding of DSS1, and that loss of
this interaction in the D2723H mutant BRCA2 protein promotes constitutive CRM1 binding,
consistent with the nuclear export and cytoplasmic mis-localization of the mutant protein.
The results in Figure 4c similarly provided biochemical evidence that RAD51 contains
CRM1-binding NESs that are ‘masked’ by interaction with the BRC4 region of BRCA2.
The F86E form of RAD51 which we have previously characterized28,30 was used in these
experiments to enable its purification without the spontaneous in vitro aggregation that is
typical of wildtype recombinant RAD5128,34. A GST-tagged version of this protein bound to
CRM1 in the presence of Ran-GTP (Figure 4c, compare lanes 3 and 4). The addition of
BRCA2 BRC4 prevented CRM1 binding (Figure 4c, lane 4) in a dose-dependent manner
(Figure 4d). Notably, a mutant form of RAD51 (SAM208-210LEA, denoted RAD51-SAM),
which we have previously shown28,30 to be incapable of BRC4 binding, interacted
constitutively with CRM1 whether or not BRC4 was present (Figure 4d, lanes 5 and 6).
Thus collectively, these in vitro results recapitulating exportin-cargo interactions using
recombinant proteins provided strong biochemical evidence for a model wherein CRM1-
dependent nuclear export – and its ‘masking’ by protein-protein interactions - is a critical
determinant of BRCA2 and RAD51 localization.
Our attempt at en-bloc replacement of consensus hydrophobic residues within the proposed
NESs (by Ala substitution of Leu2686, 2688, 2696/Ile 2694 in the BRCA2 stretch from aa
2682-2698, and Leu245, 249, 253, 255 in the RAD51 stretch from aa 245-260) proved
beyond the scope of this work, because the BRCA2 and RAD51 domains encoding the
putative NESs exhibited poor yield and solubility in bacterial expression. Moreover, further
mutational analysis of contributions made by residues located outside these motifs is
difficult because the exact length and nature of the NES sequences required for CRM1
binding are reported to be variable33,35 as are the potential binding modes between CRM1
and its various substrates36. Future structural work will be required to precisely define the
residues contributing to NES activity.
A heterozygous D2723H mutation in BRCA2 mislocalizes RAD51
Our findings suggest that the nuclear retention of BRCA2 and RAD51 depends on NES-
masking interactions between BRCA2 and DSS1, and BRCA2 and RAD51. To investigate
whether these interactions are inter-dependent, we first tested the effect on RAD51
localization of BRCA2 depletion using RNAi (Figure 5a). We used an automated
microscopic assay, wherein the nucleo-cytoplasmic difference is calculated by subtracting
the amount of RAD51 in a cytoplasmic ring surrounding the nucleus from the amount of
RAD51 in a circular area within the nuclear boundary (as defined by DNA staining) (Figure
5a, inset). We found that depletion of BRCA2 by RNA interference decreased the nuclear
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localization of RAD51 (Figure 5a and Supplementary Figs 3a-c), consistent with a role for
BRCA2 in the nuclear retention of RAD51.
Since humans who inherit the D2723H mutation on a single allele of BRCA2 are
predisposed to cancer, this raises the possibility that the mutant protein exerts a trans-
dominant effect on RAD51 localization when in the heterozygous state. Accordingly, we
examined RAD51 localization in murine embryonic stem (ES) cells engineered to be
heterozygous for the human BRCA2 D2723H mutant, in comparison to an appropriate WT
control in an identical genetic background20. In this system, one allele of murine (mm)
Brca2 was disrupted by gene targeting, and the cells complemented with a bacterial artificial
chromosome (BAC) containing a segment of human chromosome 13, encoding human
(hs)BRCA2. The BAC is reported to drive near-endogenous expression of BRCA2, and
suffices to replace mmBrca2 function in these cells, evidenced by rescue of lethality when
the second endogenous mmBrca2 allele is also disrupted20. The total levels of BRCA2 and
RAD51 expression are comparable in ES cells expressing either wildtype or D2723H forms
of BRCA2 (Supplementary Figs 4a-b). We examined the distribution of RAD51 in these
cells by biochemical fractionation and quantitative western blotting (Figure 5b), due to
technical difficulties in performing accurate microscopic analyses of protein localization in
the ES cells.. We observed an increase in cytoplasmic RAD51 in cells carrying a single
allele of D2723H BRCA2, with a corresponding decrease in nuclear levels of the protein
(Figure 5b-c), whether in the absence (Figure 5d) or presence (Figure 5e) of DNA damage
induced by mitomycin C (MMC). Mutant D2723H BRCA2 expressed from the BAC in
these cells was also predominantly cytoplasmic, unlike WT BRCA220 (Figure 5d-e).
Together, these findings suggest a mechanism underlying the deleterious effects of the
BRCA2 D2723H mutant when present in the heterozygous state co-expressed with wildtype
BRCA2.
BRCA2 and DSS1 promote RAD51 nuclear enrichment after DNA damage
There is evidence that RAD51 is enriched in the nucleus during the response to genotoxic
lesions repaired by homologous recombination37,38. We characterized this further by
analyzing the nucleo-cytoplasmic distribution of RAD51 following DNA damage in human
cells using automated microscopy. Exposure to the DNA damaging agents etoposide and
MMC caused a significant increase in the relative amount of nuclear RAD51, as evidenced
by changes in the nuclear-cytoplasmic difference of average pixel intensities within the
respective regions (Figure 6a, and Supplementary Fig S5). Moreover, genotoxins (eg.,
MMC, carboplatin, the PARP inhibitor Ku59848, hydroxyurea or aphidicolin) generating
DNA lesions known to engage pathways for repair by HR enhanced the nuclear enrichment
of RAD51 to a greater degree than other genotoxins (Figure 6b). Depletion of the damage
response kinases39 ataxia-telangiectasia mutated (ATM), ATM-and-Rad53-like (ATR), or
CHK1 diminished the nuclear enrichment of RAD51 following MMC exposure, confirming
that this response depends on the cellular pathways that sense and signal DNA damage
(Figure 6c, Supplementary Fig S6). Notably, depletion of BRCA2 or DSS1 also affected the
nuclear enrichment of RAD51 after genotoxic stress (Figure 6d, Supplementary Fig S6).
Finally, using Flag-BRCA2 complemented EUFA-423 cells (Supplementary Fig S7), we
showed that DNA damage also increases the levels of nuclear BRCA2, as measured with the
Cellomics ArrayScan (Supplementary Fig S7c), and that the depletion of DSS1 causes a
decrease in nuclear Flag-BRCA2 (Supplementary Fig S7d), Collectively, these results
suggest that the enhanced nuclear distribution of RAD51 is a DNA damage response
dependent on BRCA2 and DSS1, which may be compromised by cancer-associated
mutations that disrupt the DSS1-BRCA2 interaction.
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Discussion
The findings we report here suggest a new mechanism controlling the intracellular
distribution of the RAD51 recombinase (Figure 7), wherein NESs present in BRCA2 and its
cargo RAD51 must be masked by complex formation between BRCA2, DSS1 and RAD51
in order to permit nuclear localization. The NES-masking mechanism suggested by our
findings reveals an additional layer of regulation not recognized in earlier work reporting
that RAD51 enters the nucleus only when bound to a partner, RAD51C38, which contains an
NLS.
The location of the proposed NESs near the hydrophobic protein cores (Figures 2c and 3c)
raises the possibility that these motifs are exposed for CRM1 binding by unfolding in the
absence of the masking partner protein, suggesting a mechanism to ensure that only
functional BRCA2-DSS1-RAD51 complexes are retained in the nucleus. Moreover, RAD51
oligomerization is also likely to regulate its nuclear localization. Both in vitro and in
vivo30,34, an equilibrium is believed to exist between RAD51 monomers and oligomers of
varying stoichiometry, whose abundance is closely regulated by interaction with factors like
RAD52 or the BRC repeats of BRCA240. Although RAD51 monomers (37kDa) may pass
freely into the nucleus, RAD51 oligomers (≥74kDa) are unlikely to equilibrate passively
across nuclear pores, which generally accommodate substrates ≤60kDa (reviewed in41).
There is structural28, biochemical34 and cell biological28,30 evidence that RAD51
oligomerization is suppressed by its interaction with the BRC repeats of BRCA2. This may
help create a pool of monomeric RAD51 in the cytoplasm for transport into the nucleus
through free nuclear pore entry, or for binding to partner proteins (including RAD51C) that
contain NLSs. The RAD51 monomer-oligomer equilibrium could also exist within the
nucleus, but is likely to be biased towards DNA-bound oligomers, or monomers in which
BRC binding obscures the NES, thus promoting nuclear retention.
Depletion of DSS1, which not only binds to BRCA2 but is also a component of the 19S
proteasome42 and RNA processing complexes43, impairs the assembly of RAD51 into foci
at sites of DNA damage44 to mediate homologous DNA recombination (HR). This has
previously been ascribed to a direct function of the BRCA2-DSS1 complex in binding to
ssDNA via the formation of OB folds19, which may not only localize RAD51 to these
substrates but also displace the ssDNA-binding protein RPA11. Our findings suggest an
additional function for DSS1 in HR, through regulation of the nuclear localization of
BRCA2 and indirectly, RAD51. In this light, it is notable that mutant forms of BRCA2 in
which the DSS1 binding domain has been entirely deleted, are still capable of supporting
HR45-47. Moreover, DSS1 is apparently required for HR only when the DBD is present48.
These observations are consistent with our findings: DBD deletion presumably removes the
strong NESs identified in this work, obviating the necessity for their ‘masking’ by DSS1,
and allowing mutant forms of BRCA2 lacking the DBD to at least partly function in the
nucleus even without DSS1.
We surmise that DBD deletion and loss of DSS1 binding in human BRCA2 may lead to
subtle defects in HR, reminiscent of the phenotypes observed in mutants of the BRCA2
homologue Brh2 in the fungus U. maydis that lack DSS1 binding49. On the other hand, the
NESs we have identified in human BRCA2 are not well conserved in Brh2 (Figure 2a),
raising the possibility that the mechanisms which regulate BRCA2 nuclear localization are
not directly comparable between these species. However, U. maydis RAD51 contains a
conserved NES (Figure 3a), suggesting its localization may depend on the BRC repeat found
in Brh2, whereas S. cerevesiae RAD51 does not (Figure 3a), consistent with the absence of a
BRCA2 homologue in yeast.
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Several lines of evidence suggest that the DSS1-masked NES we have identified in BRCA2
is dominant in its function over other motifs within the protein that may control nuclear
localization24,50. For instance, both the D2723H and the W2725A point mutants of BRCA2,
which lack DSS1 binding to mask the NES, mis-localize to the cytosol, and the D2723H
variant is embryonic lethal in mice when homozygous20, suggesting it is non-functional.
Moreover, our findings suggest that these point mutations are unlikely to exert their effects
simply through BRCA2 destabilization, because protein expression is not markedly
decreased. Instead, they speak to a critical role for the DSS1-BRCA2 interaction in the
control of BRCA2-RAD51 localization. These findings raise questions regarding the
expected clinical effects of the cancer-associated BRCA2D2723H allele when expressed in
the heterozygous state in germline mutation carriers. Although our findings suggest that
BRCA2D2723H heterozygosity may suffice to mislocalize RAD51, we are unaware that
carriers of this mutation exhibit radiosensitivity or other clinical features associated with
profound defects in DNA repair, consistent with the lack of radiosensitivity of D2723H cell
lines in vitro (Supplementary Fig 4c). However, patients heterozygous for BRCA2D2723H do
appear to be at risk of developing early-onset cancers, suggesting that this alteration causes a
cumulative rather than acute effect on genome stability, which acts over years to promote
carcinogenesis. Indeed, BRCA2 is often cytoplasmic in cancer cells24, and mislocalization
of RAD51 has been reported in both familial breast cancer51 and sporadic cases of prostate
cancer52.
Notably, our findings also indicate that alterations in the normal intracellular distribution of
RAD51 may mark defects in the cellular response to DNA damage arising at several distinct
steps (Figure 6c-d). We therefore suggest that quantitative measurement of the nucleo-
cytoplasmic levels of RAD51 may serve as a surrogate marker for these defects, which may
be of value in assessments of cancer diagnosis or therapeutic responsiveness.
OnlineMethods
Antibodies and siRNA
Antibodies used in this work were:
Antibody Application and dilution Comments
1 anti-RAD51 [14B4]
(Genetex)
WB (1:2000)
2 Anti-RAD51 B01P
(Abnova)
IF (1:2000)
3 anti-RAD51
(Ab1; Calbiochem)
IF (1:1000) Polyclonal serum
(batches prior to
2010)
4 anti-Flag
(M2;Sigma F1804)
WB (1:3000), IF (1:2000)
5 anti-DSS1 (goat
polyclonal; Abcam,
Ab5649)
WB (1:1000), IF (1:500)
6 anti-GFP Clontech
632460
WB 1: 2000
7 anti-GFP Clontech
632381
IP (1ul per mg of lysate) Polyclonal
serum, suitable
only for IP
8 anti-GFP
(MBL-598)
IF (1:1000)
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Antibody Application and dilution Comments
9 anti-SCC1 (rabbit
polyclonal –abcam
Ab992
WB (1:2000)
10 anti-MEK2(BD
Transduction
LaboratoriesCat.No.
610236)
WB 1:3000
11 Anti BRCA2
(Ab1/OP95, Merck)
WB 1:500 Human BRCA2
12 Anti BRCA2 H-300
(Santa Cruz),
WB 1:500 Pan-species
siRNA sequences targeting the following mRNAs were:
BRCA2 (Dharmacon siGenome) GAAACGGACUUGCUAUUUA
GUAAAGAAAUGCAGAAUUC
GGUAUCAGAUGCUUCAUUA
GAAGAAUGCAGGUUUAAUA*
(* also used as single siRNA)
BRCA2 (Qiagen, 5′UTR) TTGGAGGAATATCGTAGGTAA
Chk1 (Dharmacon siGenome) GCAACAGUAUUUCGGUAUA
GGACUUCUCUCCAGUAAAC
AAAGAUAGAUGGUACAACA
CCACAUGUCCUGAUCAUAU
ATM (Dharmacon siGenome) GCAAAGCCCUAGUAACAUA
GGGCAUUACGGGUGUUGAA
UCGCUUAGCAGGAGGUGUA
UGAUGAAGAGAGACGGAAU
ATR (Dharmacon siGenome) GAACAACACUGCUGGUUUG
GCAACUCGCCUAACAGAUA
UCUCAGAAGUCAACCGAUU
GAAUUGUGUUGCAGAGCUU
DSS1 (Eurofins MWG Operon) GCAGCCGGUAGACUUAGGU
GAGUUCCCUGCCGAAGACU
UGUAGAGGAUGACUUCUCU
GAUGAAGAUGCACAUGUCU
Plasmids and Cloning
NLS-SYFP-DBD—The BRCA2 DBD was cloned between nt7382 and 8926, to generate
fragments spanning the residues from 2461 to 2975 in HsBRCA2, using the primers:
FOR 5′- AAGCCCAGAAAGGGTGCTTCTTCAAC
REV 5′- GCACCCTTTCTGGGCTTAGGCATC
These fragments were cloned into the vectors pEF-Myc-Nuc, and pEGFP-C1-NotI
(generated previously in our lab to contain an extra Not1 site in the MCS). The EGFP-DBD
plasmid was then digested to release the EGFP tag, which was replaced with an NLS-
containing version of SYFP for nuclear localization, using the primers
FOR (including NLS tag)
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5′-GGCCGCTAGCATGGATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAA
AGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTAGTGAGCAAGG
GCGAGGAGCTGTTCA-3′
REV 5′- GAATCTCGAGTCTTGTACAGCTCGTCCATGCCGAGAGT- 3′
from the plasmid pSYFP2-C1 (kind gift of Dr. Theodorus Gadella, Amsterdam,
Netherlands)
The W2725A and D2723H mutation for disruption of DSS1 binding was introduced into
these plasmids using the QuickChange mutagenesis kit (Stratagene) and the primer NdeI-
W2725A, and NcoI-D2723H.
5′- TTGAACTTACAGATGGGGCATATGCTGTTAAGGCCCAGTTAG- 3′
5′- GCCATTATTGAACTTACCCATGGGTGGTATGCTGTTAAGG- 3′
Mutations were generated with the Quikchange XL site-directed mutagenesis kit
(Stratagene) according to the manufacturer’s instructions, with the exception that the
digestion of the parental DNA template with DpnI was for 4 h.
Cloning of the RAD 51 Nuclear Exclusion signal—Rad 51 F
GATCCAGGCAGATGCACTTGGCCAGGTTTCTGCGGATGCTTCTGCGACTCGCTG
ATGAGTTTGGTTGAG
RAD51 R
AATTCTCAACCAAACTCATCAGCGAGTCGCAGAAGCATCCGCAGAAACCTGGCC
AAGTGCATCTGCCTG
pSYFP-C1 was digested with BglI and EcoRI, before ligation with the annealed product of
RAD51 F & R primers. The annealed primers spanned aa 241-260 of human RAD51 and
resulted in in-frame fusion with SYFP.
Cloning of the BRCA2 NES—BRCA2 NES-F
GATCCGCAAAAACACTTGTTCTCTGTGTTTCTGACATAATTTCATTGAGCGCAAA
TATATGAG
BRCA2 NES-R
AATTCTCATATATTTGCGCTCAATGAAATTATGTCAGAAACACAGAGAACAAGT
GTTTTTGCG
BRCA2 Control-F
GATCCGTTAAGGCCCAGTTAGATCCTCCCCTCTTAGCTGTCTTAAAGAATGGCA
GACTGACAGTTGGTCAGTGAG
BRCA2 Control-R
AATTCTCACTGACCAACTGTCAGTCTGCCATTCTTTAAGACAGCTAAGAGGGGA
GGATCTAACTGGGCCTTAACG
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pSYFP-C1 was digested with BglI and EcoRI and ligated with the annealed product of the
primers described above to yield the SYFP-NES and SYFP-control sequences.
Flag-BRCA2 and Flag-BRCA2 D2723H—The pCAG-FLAG-BRCA2-IRES-Neo
plasmid was generated in a 2-step procedure. p3xFLAG-BRCA21 was modified by
introducing IRES fragment from pIRES-Neo vector (Clontech) to generate a FLAG-tagged
BRCA2 and Neomycin resistant gene in a single transcript. Then, the 3xFLAG -BRCA2 -
IRES-Neo fragment was inserted to the pCAG-GFP vector (Addgene) and the GFP and
SV40 early promoter regions were removed to obtain the stable expression of the Flag-
BRCA2 protein in SV40 transformed cells. The D2723H mutation was obtained using the
quickchange mutagenesis kit and the primer (NcoI-D2723H):
5′- GCCATTATTGAACTTACCCATGGGTGGTATGCTGTTAAGG- 3′
Flag-DSS1 and Cherry-DSS1—To make the Flag-DSS1 construct, full-length (70 amino
acids) hDSS1 sequences were cloned into HindIII and BamHI sites of 3xFlag CMV10
vector (Sigma). The primers used are:
For 5′-GTCAAGCTTTCAGAGAAAAAGCAGCCGGTAGAC-3′
Rev 5′-GGCGGATCCCTATGAAGTCTCCATCTTATAAC-3′
To make the mCherry-DSS1 construct, full-length hDSS1 sequences were cloned between
BstB1 and BamHI sites, excising RAD51 from a previously described2 mCherry-RAD51
vector. The primers used were:
For 5′-GCGTTCGAATATGTCAGAGAAAAAGCAGCCGGTAG-3′
Rev 5′-CGCGGATCCCTATGAAGTCTCCATCTTATAAC-3′
SYFP-RAD51, SAED—To make the SYFP-RAD51 and SYFP-RAD51-SAED constructs,
full-length SYFP sequences (from pSYFP-C1) were cloned into AgeI and SacI sites,
excising EGFP from EGFP-RAD51 and EGFP-RAD51 SAED (previously described). The
primers used are:
For 5′ ATACCGGTATGGTGAGCAAGGGCGAGGAGCTGTT 3′
Rev 5′ ATGAGCTCGCTTGTACAGCTCGTCCATGCCGAGAGT 3′
GST-DBD/RAD51—To make GST-DBD construct for in vitro binding assay, BRCA2
DBD (from amino acid residue 2461 to 2975 in hsBRCA2) was PCR-amplified from the
NLS-SYFP-DBD construct and cloned into SalI and NotI sites of the vector pGEX-4T3 (GE
Healthcare). For GST-DBD D2723H, the same region was PCR-amplified from the NLS-
SYFP-DBD D2723H construct.
The primers used are:
For 5′-GCGTCGACAACTCCAATCAAGCAGCAGCT-3′
Rev 5′-GCGCGGCCGCTCATACAATACGCAACTTCCACAC-3′
To make GST-RAD51 F86E and GST-RAD51 SAM constructs, the respective RAD51
mutant sequences were PCR-amplified from GFP-RAD51 F86E and GFP-RAD51 SAM
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constructs3 and cloned into SalI and NotI sites of the vector pGEX-4T3 using the following
primers.
For 5′-GCGTCGACATGGCAATGCAGATGCAGCTT-3′
Rev 5′-GCGCGGCCGCTCAGTCTTTGGCATCTCCCACT-3′
His-DSS1—To make His-DSS1 construct, full-length hDSS1 sequences were cloned into
NdeI and BamHI sites of modified pET28a Vector (Novagene). The primers used were:
For 5′-GCGCCATATGTCAGAGAAAAAGCAGCCG-3′
Rev 5′-GCGCGGATCCCTATGAAGTCTCCATCTTATAACC-3′
hCRM1 and hRanQ69L constructs for bacterial overexpression are gifts from Dr Dirk
Gorlich4,5 (MPI, Gottingen)
BRC4 peptides were synthesized by Cambridge Research Biochemicals Ltd with an N-
terminal biotin moiety attached through a 6-aminohexanoic acid spacer and a C-terminal
amide. The sequence of the peptide is:
KEPTLLGFHT ASGKKVKIAK ESLDKVKNLF DEKEQ
Cell culture and transfection
293T and U2OS were cultured in sterile-filtered growth medium (Dulbecco’s Modified
Eagle Medium (D-MEM) with GlutaMAX-1, 4500 mg/L D-glucose, sodium pyruvate and
pyridoxine (Gibco), supplemented with 10% fetal calf serum (FCS) (Gibco) and 2%
penicillin streptomycin (Gibco)) in a 37°C humidified incubator in the presence of 5% CO2.
Cells were split every 2-3 days and maintained at 50% confluency. MCF10A cells were
grown in D-MEM/F12 (1:1) with 15mM HEPES buffer (Gibco) supplemented with 5%
horse serum (Invitrogen), 10 μg/ml insulin (Sigma), 20 ng/ml EGF (Sigma), 100 ng/ml
cholera toxin (Sigma), 500 ng/ml hydrocortisone (Sigma) and 1% penicillin streptomycin.
ES cells were grown in gelatinized plates with GMEM medium (Sigma) supplemented with
15% FBS (Hyclone), 1mM sodium pyruvate, 1x non-essential amino acids (Invitrogen)
1xglutamate-penicillin-Streptomycin, (Invitrogen), 100uM β-mercaptoethanol and 1000
units per ml of Leukemia inhibitory factor (ESGRO Chemicon).
Transient transfection of DBD plasmids was performed by lipofection using lipfectamine
2000 (Invitrogen) using 1μg DNA and 3μl Lipofectamine in OptiMEM (Invitrogen) for 106
cells. For high content microscopy, U2OS cells were plated in a 24-well plate. One day post
plating cells were transfected with NLS-SYFP-DBD construct, WT or D2723H mutant
(0.25μg), together with an empty mCherry plasmid or mCherry-DSS1 plasmid (0.125μg),
using lipofectamine. Full length BRCA2 was introduced into U2OS cells using Amaxa Cell
Line Nucleofector Kit V and Nucleofector I Device with the Program X-01 (Lonza). For
high-content microscopy experiments, MCF10A cells were reverse transfected with
indicated siRNAs with final concentration of 25nM using Dharmafect I transfection reagent
(Fermentas GmbH, Thermo Fisher Scientific), in a 96-well plate. EUFA423BRCA2 (EUFA-
BRCA2#34) cell lines were established by stably transfecting EUFA423 cells (SV40
immortalized BRCA2 deficient human fibroblasts) with the pCAG-FLAG-BRCA2-IRES-
Neo construct in a standard DMEM 10% FBS with P/S supplemented with 750 μg/ml G418.
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Cell viability assay
Cells were plated into 96-well plates at a density of 8000 cells per well. Different doses of
mitomycin C (Sigma) were added (4 wells per dose/cell line), and the plates were incubated
at 37°C for five doubling times. CellTiter-Blue reagents (Promega) were added to each well
of the 96-well plate according to the manufacturer’s guidelines. The plates were incubated at
37°C for approximately 1-2 hour in a humidified 5% CO2 atmosphere. Number of viable
cells was determined using the Fusion plate readerat A590 nm. A similar procedure was
followed for the cell viability assay on ES cells exposed to different doses of ionizing
radiation using a Faxitron X-ray unit.
Lifetime measurement
DBD and DSS1 transfected cells were plated on MatTek poly-d-lysine coated, No.1 glass
bottomed 35mm dishes and media replaced with phenol red free L15. Experiments were
performed on a Time-Correlated Single Photon Counting (TCSPC) system (Becker and
Hickl Inc., SPC 830) connected to the de-scanned and fibre-coupled output of an Olympus
FV300 confocal scanner (Laser Analytics Group, Department of Chemical Engineering). A
supercontinuum laser (Fianium Inc, SC400) was used as the illumination source. An
excitation wavelength of 436nm (+/− 1nm) was selected by an Acousto Optic Tunable Filter
(AOTF) and coupled into the confocal scanner. The fluorescence output was filtered
between 480nm and 550nm before being detected by the TCSPC photomultiplier tube.
TCSPC data were analyzed to generate lifetime information on dedicated MATLAB
(Mathworks, inc) and Becker and Hickl software by Simon Schlachter (Cambridge, UK).
Immunofluorescence analysis
Cell staining and immunofluorescence analyses were carried out as described previously6.
Briefly, transfected and untransfected cells were grown on coverslips and subjected to
different treatments as indicated in the text prior to fixation. Cells for IF experiments were
grown on coverslips to 70–80% confluence, washed in PBS and fixed in 4%
paraformaldehyde or 95% Ethanol+5% Acetic acid. The cells were permeablized by adding
TBS with 0.1% Triton and 0.2%Tween for 5 min, blocked in TBS-Triton-Tween + 2%
BSA) and incubated with the primary antibody and secondary antibody in a humidified
chamber with TBS-Tween-Triton washes in between. The coverslip is then mounted onto a
slide for viewing using a mounting medium with DAPI. Immunofluorescence images were
captured using a Zeiss Axiovert200 LSM510meta confocal microscope using a 40x
objective with fixed optical slice, laser power and detector/amplifier settings for all samples
across each individual experiment to allow comparison.
High content microscopy for adherent cells
High content microscopy experiments were performed on the Cellomics VTI-Arrayscan
Instrument (Thermofisher) as described previously6; 96 well plates (Nunc) with cells seeded
at 3000/well, or in 24 well plates. Transfections were performed using 0.25μg or 0.125μg of
DNA and lipofectamine. The cells were treated with specified DNA damaging agents, fixed
with 4% formaldehyde for 10 min, immunostained as per conventional protocols, and
incubated with 0.1% Triton X-100 with Hoechst 33342 DNA dye for 10 min, followed by
PBS washes. Cellomics VTI ArrayScan was used for image acquisition using the
Compartmental Analysis BioApplication, using a 40x non-immersion objective. Hoechst
staining was used for object identification and the average intensity of fluorescent signal per
nucleus was estimated using the target activation Cellomics bio-application. 300-500 cells
were analyzed per well, and standard errors calculated from an average of the means of
multiple wells.
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Immunoprecipitation
Whole cell extracts were prepared from 15×106 293T cells 24 hours after transfection. The
trypsinized or scraped cells were spun down in a Beckman Centrifuge at 1000 rpm for 3
minutes, washed once with PBS, and resuspended in 1ml of ice-cold immunoprecipitation
lysis buffer (50mM HEPES, pH7.4, 100mM NaCl, 0.5% Nonidet P-40 (NP-40), 10mM
EDTA, 2mM β-glycerophosphate, 1mM DTT, 1mM PMSF supplemented with protease
inhibitors (Roche)) for 15 minutes on ice. Extracts were then spun down in an Eppendorf
centrifuge for 15 minutes at 12,000 rpm and the supernatant was collected and quantified for
protein concentration by the biocinchoninic acid (BCA) assay (Sigma). 1mg of whole cell
extract was precleared with 30μl of a 50% slurry of protein A-Sepharose (Sigma) for 20
minutes at 4°C with gentle shaking to reduce non-specific protein-bead interactions,
followed by immunoprecipitation using 1-2μg of antibody and 30μl of a 50% slurry of
protein A-Sepharose overnight in the cold room with gentle shaking. The immune
complexes were then washed 4 times in ice-cold immunoprecipitation lysis buffer and 1
time in PBS before resuspension in 4xloading buffer (Invitrogen) and 50mM DTT.
In-vitro pull-down assays
The in-vitro CRM1 binding assays were performed using an assay described previously33.
For each assay condition, 1 μg of GST tagged protein (DBD or DBD-D2723H or RAD51-
F86E or RAD51-SAM) bound to glutathione-separose 4B beads was incubated with 1 μM
CRM1/RanGTP for 1 h at 4°C in 500 μL of binding buffer (50 mM Hepes (pH7.5), 150 mM
NaCl, 25 mM KCl, 50 mM LiCl, 2 mM Mg(OAc)2, 5 mM DTT and 20 μM GTPγS (a non-
hydrolysable GTP analogue). DSS1 proteins or BRC4 peptides (or binding buffer alone for
GST control) were then added to individual tubes as indicated, followed by incubation at
4°C for 2 h. Beads were washed three times with 500 μL of binding buffer, followed by
elution of proteins and SDS-PAGE electrophoresis. DBD, DBD-D2723H, RAD51-F86E and
RAD51-SAM were detected by immunoblotting with anti-GST antibody and CRM1 was
detected by immunoblotting with anti-His antibody.
Cell Fractionation
Cells were washed in PBS and resuspended in solution A (10 mM Hepes [pH 7.9], 10 mM
KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 1 mM DTT, protease and phosphatase
inhibitors). Cells were incubated on ice for 5 min, and the cytoplasmic (S1) and nuclear
fractions (P1) were harvested by centrifugation at 1,300 × g for 4 min. Isolated nuclei were
then washed in solution A, lysed in solution B (0.1% Triton X-100, 3 mM EDTA, 0.2 mM
EGTA, 1 mM DTT, protease and phosphatase inhibitors), and incubated on ice for 10 min.
The soluble nuclear (S3) and chromatin fractions were harvested by centrifugation at 1,700
× g for 4 min. To release chromatin-bound proteins by nuclease treatment, the P2 fraction
was incubated in buffer A plus 1 mM CaCl2 and 5 U micrococcal nuclease for 15 min at
37°C, after which the reaction was stopped by the addition of 1 mM EGTA and spun down
at 10,000 × g to collect the supernatant enriched for chromatin proteins (P3). The S3 and P3
fractions were pooled to obtain a nuclear extract.
Proteins were resolved on 3-8% Tris-Acetate SDS-PAGE (Invitrogen) for BRCA2
experiments, 4-12% MES SDS-PAGE (Invitrogen) for most other experiments, and 4-20%
Tris Glycine gels for DSS1 experiments. Transfer was performed to PVDF membranes
(Immobilon-P, Millipore) at 30V for 2hours. Western blots were blocked in 5% milk
(Marvel) and 0.5% Tween-20 in TBS for 30min at room temperature before probing with
the appropriate primary antibodies. Western blots were developed with HRP-conjugated
secondary antibodies against rabbit and mouse at 1/15000 and 1/10000 respectively, and
detected with either ECL or ECL Plus detection reagents (Amersham) and exposed to CL-
Xposure™ Film (Pierce).
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Quantitative RT-PCR
Gene Sequence
GAPDH FW: -TGAGCTTGACAAAGTGGTCG;
REV: –GTCAGTGGTGGACCTGACCT;
CHK1 FW: -CCAGATGCTCAGAGATTCTTCCA;
REV: - TGTTCAACAAACGCTCACGATTA;
ATM FW:–GGCTATTCAGTGTGCGAGACA;
REV: –TGGCTCCTTTCGGATGATGGA;
ATR FW:-TCCCTTGAATACAGTGGCCTA;
REV: -TCCTTGAAAGTACGGCAGTTC.
DSS1 FW:-GAAAAAGCAGCCGGTAGACTT,
REV: ATCCCAATTATCCTCCCAGACA
BRCA2 FW:-TTGGCTGATGGTGGATGGCTCATA,
REV: TTTGGATCCACACCTGGAGTGTCA
To analyse the effects of siRNA knockdown, 0.5 μg of total RNA, extracted with Rneasy
Plus Mini Kit (Qiagen), was used for cDNA synthesis using Cloned AMV First-Strand
Syntehesis kit (Invitrogen). Q-PCR was performed using the LightCycler 480 SYBR Green I
Master mix (Roche) with the primers listed above. The Ct values were obtained from the
LightCycler 480 and referenced to the expression of the GAPDH housekeeping gene. All
samples were then normalized to Non-Targeting siRNA pool (Fermentas GmbH).
For the RT-PCR comparison between MmBrca2 and HsBRCA2, the following primers were
used:
GAPDH Primers
F GAAGGTCGGTGTGAACGGATTT
R CATTTGATGTTAGTGGGGTCTC
Mouse Brca2 primers
5022F TTATGCAGGAATCTTTGGACA
5173R AGTTCTGCATTTCTTCACATTTT
Human BRCA2 primers
731F AAAGTTTGTGAAGGGTCGTC
840R TAAGGGTGGGTGGTGTAGC
RNA made from exponentially growing ES cells using Qiagen total RNA kit. 2ug RNA was
converted into cDNA using Roche Transcriptor High Fidelity cDNA synthesis Kit, and Real
time PCR performed as described above. The Cp values were directly represented in the
figure to provide an unbiased assessment, using GAPDH as a control.
Original images of blots used in this study can be found in Supplementary Figure 8.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. DSS1 binding correlates with localization of BRCA2
a) is an immunoprecipitation experiment of YFP tagged NLS-DBD fragments with Cherry-
DSS1 in 293T cells, using an anti-GFP polyclonal serum. The left panels are of the whole
cell lysate (10% of the input), and the panels on the right are of the immunoprecipitate.
Transfection of free SYFP with cherry-DSS1 serves as the negative control for the western
blot as well as for the immunoprecipitation, and endogenous BRCA2 as the loading control
for the experiment. Endogenous DSS1 is difficult to visualize on standard Western blots due
to its acidity and small size, requiring unique gel and transfer conditions sub-optimal for the
relatively large DBD fragment. Uncropped blots are in Supplementary Fig 8. b) is a dot plot
of the mean SYFP lifetime per cell from a FRET-FLIM experiment with NLS-SYFP-DBD
and Cherry-DSS1. Each dot represents a single cell; the lines and error bars represent the
mean and 95% confidence interval for the population studied in the experiment. U2OS cells
co-transfected with the indicated constructs were analyzed by TCSPC. NLS-SYFP DBD
forms have a lifetime of about 3200ps, which drops to about 2900ps when mCherry-DSS1 is
co-transfected (p<0.01 by two-tailed Student’s t-test, n~30), in contrast to the mutant forms
of the DBD. c) shows representative immunofluorescent confocal micrographs of 293T cells
nucleofected with Flag-tagged full-length versions of BRCA2, WT or mutant D2723H and
W2725A. DNA is colored in red, BRCA2 (anti-Flag) in Cyan, and endogenous DSS1 (anti-
DSS1) in Magenta.
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Figure 2. DSS1 regulates a functional NES in BRCA2
a) is a clustal W alignment of the nuclear exclusion signal within the DBD of BRCA2, with
the critical hydrophobic residues that potentially contribute to the NES consensus marked by
black boxes. b) is a representative fluorescent micrograph of 293T cells transfected with a
BRCA2 NES-SYFP construct (upper panel) and SYFP tagged to a similarly sized sequence
within BRCA2 (lower panel), which serves as a negative control. c) is a rendering of the
1YIJ structure of rnBRCA2 DBD. The DBD is shown in grey, and the critical hydrophobic
NES residues highlighted in blue. Mutations that affect DSS1 binding are depicted in red.
The right panel shows a superimposition of DSS1 (green).
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Figure 3. BRCA2 regulates a functional NES in RAD51
a) is a histogram of the NES scores for amino acids in the HsRAD51 sequence, as
determined by the NetNES algorithm, showing the potential NES sequence in the C-
terminus of the protein. b) is a sequence alignment of the residues comprising the RAD51
NES from yeast to human. The hydrophobic residues are marked by black boxes. c) is a
rendering of the crystal structure 1N0W, in the same color scheme as Figure 2c. NES
residues in RAD51 are shown in blue. The right panel shows a superimposition of the BRC
repeat (green). d) shows representative micrographs of 293T cells transfected with a
RAD51-NES tagged version of SYFP (right), in comparison to free SYFP alone. e) is a
fluorescence micrograph of SYFP-tagged wildtype RAD51, compared with a mutant form
lacking BRCA2 binding (SYFP-RAD51 (SA-ED)). SYFP-tagged proteins were expressed in
Rad51−/−DT40 cells that conditionally express Tet-regulated untagged RAD51.
Micrographs were taken 12h after the depletion of untagged RAD51 using doxycycline 30.
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Figure 4. CRM1 binding to NESs in BRCA2 or RAD51 is masked by DSS1 or BRC4 respectively
a) Immunoblots of GST pull-down assessing binding of CRM1 to GST-DBD and GST-
DBD-D2723H immobilized on a glutathione sepharose matrix in the absence (lanes 3 and 5)
or presence (lanes 4 and 6) of DSS1 at the 5-fold molar excess optimized from the
representative titration shown in panel b). GST was used as a specificity control. DSS1
inhibits the binding of CRM1 to DBD (lane 4) but not to DBD-D2723H (lane 6). c)
Immunoblots of GST pull-down assessing binding of CRM1 to GST-RAD51-F86E and
GST-RAD51-SAM immobilized on a glutathione sepharose matrix in the absence (lanes 3
and 5) and presence of (lanes 4 and 6) of BRC4 peptide at the 6-fold molar excess optimized
from the representative titration shown in panel d). GST was used as a specificity control.
BRC4 peptide disrupts the binding of CRM1 to RAD51-F86E (lane 4) but not to RAD51-
SAM (lane 6). Proteins were visualized with antibodies against His or GST. CRM1 protein
was His-tagged. Uncropped blots are in Supplementary Fig 8.
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Figure 5. RAD51 mislocalization by BRCA2 depletion or mutation
a) is a dot plot of the mean nucleo-cytoplasmic difference of RAD51 per cell, determined
for a population of cells with and without exposure to BRCA2 siRNA. The figures in the
inset represent the algorithm used for determining the nucleo-cytoplasmic difference by
automated microscopy. The left image is of the nucleus as defined by DAPI, the middle
image is that of RAD51 staining. The algorithm for nucleo-cytoplasmic intensity difference
calculation (see Methods) is overlayed on RAD51 in the right panel. b) is a cell fractionation
experiment from heterozygous mouse ES cells, with Western blotting for RAD51 to assess
localization. MEK2 (predominantly cytoplasmic) and SCC1 (predominantly nuclear) serve
as loading controls and controls for the efficiency of fractionation. c) is a bar graph
quantitating the results from three independent fractionation experiments. The nucleo-
cytoplasmic intensity difference for RAD51 in each experiment was obtained by generating
densitometric profiles for each band (identical exposure) using ImageJ, and then subtracting
the cytoplasmic value from the nuclear value. Lower (more negative) values indicate more
cytoplasmic protein (n=3, error bars represent SEM). d) shows a cell fractionation
experiment of ES cells carrying BACs expressing either the WT or D2723H mutant of
BRCA2, in the absence or presence (E) of DNA damage induced by exposure to 100 ng/ml
of MMC for 20 hrs. SCC1 is used as a control for fractionation. One experiment
representative of 3 independent repeats is shown. Uncropped blots are in Supplementary Fig
8.
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Figure 6. RAD51 nuclear enrichment is a BRCA2-dependent DNA damage response
a) represents the frequency distribution of the RAD51 nuclear-cytoplasmic pixel intensity
difference (NC-difference) from different populations of MCF10A cells analyzed by
automated immunofluorescence microscopy. Results for untreated cells are in black, and for
cells treated with etoposide or MMC in blue or grey respectively (n=2000 each). b) shows
the mean NC-difference for RAD51 in MCF10A cells treated with the indicated forms of
DNA damage. Each bar represents the mean ± standard error of 4 wells in a 96-well plate,
with 500 cells counted per well. c) shows the mean NC-difference for RAD51 in MCF10A
cells pre-treated with the indicated siRNAs, with (grey) or without (black) exposure to
MMC. The increase in the NC-difference after DNA damage is significantly affected
(Student’s two tailed t-test, p<0.05, n=500 cells, 3 wells) by depletion of ATM, ATR or
CHK1. d) shows the RAD51 NC-difference in MCF10A cells following knockdown of
BRCA2 and DSS1 using multiple independent siRNA’s. The black bar on the left represents
undamaged cells. The nuclear enrichment seen after DNA damage is significantly affected
(p<0.01, Student’s two tailed t-test, n=500 cells, 3 wells) by depletion of both BRCA2 and
DSS1. Supplementary Fig 6a-d shows the depletion efficiency with the siRNAs used.
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Figure 7. A hypothetical model for BRCA2 and RAD51 nuclear localization through masking of
nuclear export sequences
a) depicts the proposed mechanism wherein the nuclear retention of BRCA2 (red oblong) is
allowed when its binding to DSS1 (black semi-circle) obscures an NES motif. Nuclear
transport (green arrow) is presumably directed by NLSs previously identified in the C-
terminal region of BRCA2, which are not shown. Dissociation of BRCA2 from DSS1 may
permit nuclear export (blue arrow). b) depicts the proposed mechanism wherein the nuclear
retention of RAD51 (yellow circle) is allowed when its binding to the BRC repeats of
BRCA2 obscures an NES motif. Nuclear transport (green arrow) of the BRCA2-RAD51
complex is presumably directed by the NLSs in BRCA2. In addition, cytosolic RAD51 may
exist in an equilibrium (thin blue arrows) between free monomers and oligomers.
Momomeric RAD51 is small enough to diffuse freely across the nuclear membrane (black
arrows), whereas oligomers are not. Dissociation of RAD51 from BRCA2 may permit
nuclear export (blue arrow). The net result of these different processes is to localize RAD51
predominantly in the nucleus. c) depicts how the processes depicted in the preceding panels
may be affected by the BRCA2 D2723H mutation, which prevents DSS1 binding (black X).
Mutant BRCA2 is exported from the nucleus (blue arrows) resulting in predominant
cytoplasmic localization, and this is proposed to shift the balance towards cytoplasmic
localization of RAD51, despite the presence of wildtype BRCA2.
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